Clinical Trial Detail

NCT ID NCT01905592
Title A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Tesaro, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

Niraparib

Age Groups: adult senior

Additional content available in CKB BOOST